A detailed history of Raymond James & Associates transactions in Rockwell Medical, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 20,402 shares of RMTI stock, worth $94,869. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,402
Holding current value
$94,869
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$1.67 - $4.4 $34,071 - $89,768
20,402 New
20,402 $80,000
Q4 2023

Jan 16, 2024

BUY
$1.58 - $2.44 $47,888 - $73,953
30,309 Added 15.9%
220,979 $417,000
Q3 2023

Oct 24, 2023

BUY
$1.83 - $6.19 $261,415 - $884,241
142,850 Added 298.72%
190,670 $396,000
Q2 2023

Jul 25, 2023

SELL
$1.8 - $5.46 $21,600 - $65,520
-12,000 Reduced 20.06%
47,820 $261,000
Q1 2023

Apr 14, 2023

BUY
$1.03 - $2.62 $61,614 - $156,728
59,820 New
59,820 $108,000

Others Institutions Holding RMTI

About ROCKWELL MEDICAL, INC.


  • Ticker RMTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 10,675,200
  • Market Cap $49.6M
  • Description
  • Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iro...
More about RMTI
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.